|
Orthologous residues
|
|
ATRIP (human): S224‑p, ATRIP iso2 (human): S224‑p, ATRIP (mouse): S224‑p, ATRIP (rat): S224‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mass spectrometry, phospho-antibody
|
|
Relevant cell lines - cell types - tissues:
HeLa (cervical)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Comments:
ATRIP is in the complex with ATR
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
CDK2 (human)
|
pharmacological inhibitor of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
roscovitine
|
|
|
|
decrease
|
|
|
|
Downstream Regulation
|
|
Effect of modification (process):
cell cycle regulation
|
|
Comments:
important for the G2-M checkpoint arrest in response to DNA damage
|
